Studies indicate that TIM-3 is a marker of T cell exhaustion, and therapeutic targeting of TIM-3 has shown promise in rejuvenating T cells, enabling them to persist in combating pathogens or tumor cells (Fig. 7). Here, HAVCR2 is linked to neoplasm.